Login / Signup

Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.

Mara BacchianiVincenzo SalamoneEleana MassaroAlessandro SandulliRiccardo MariottiniAnna CadenarFabrizio Di MaidaBenjamin PradereLaura S MertensMattia LongoniWojciech KrajewskiFrancesco Del GiudiceDavid d'AndreaEkaterina LaukhtinaShahrokh F ShariatAndrea MinerviniMarco MoschiniAndrea Marinull On Behalf Of European Association Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group
Published in: Cancers (2023)
18F-FDG PET/CT provides important incremental staging and restaging information that can potentially influence clinical management in MIBC patients. Standardization and development of a scoring system are necessary for its wider adoption. Well-designed randomized controlled trials in larger populations are necessary to provide consistent recommendations and consolidate the role of 18F-FDG PET/CT in the management of bladder cancer patients.
Keyphrases
  • end stage renal disease
  • randomized controlled trial
  • chronic kidney disease
  • newly diagnosed
  • lymph node
  • ejection fraction
  • prognostic factors
  • peritoneal dialysis
  • study protocol
  • health information
  • meta analyses